RTOG Foundation Study 3504
Study Date: September 27, 2018 | Status: Terminated
Safety Evaluations of Nivolumab (Anti-PD-1) Added to Chemoradiotherapy in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Principal Investigators
Maura Gillison, MD, PhD
Robert Ferris, MD, PhD
Primary Objective
To evaluate the safety of the addition of nivolumab (anti-PD-1 targeted immumotherapy) to cisplatin-based CRT, cextuximab-based CRT or RT alone in patients with intermediate or high-risk head and neck squamous cell carcinoma (HNSCC).
Patient Population
Histologically or cytologically confirmed intermediate- or high-risk HNSCC.
Participating Sites
| Institution Name | City | State/Country |
|---|---|---|
| Emory University | Atlanta | GA |
| Inova Fairfax Hospital | Falls Church | VA |
| MD Anderson Cancer Center | Houston | TX |
| Providence Portland Medical Center | Portland | OR |
| Ohio State University | Columbus | OH |
| Stanford University | Palo Alto | CA |
| University Hospitals Cleveland Medical Center | Cleveland | OH |
| University of Florida Health Cancer Center | Orlando | FL |
| University of Louisville | Louisville | KY |
| University of Wisconsin Hospital and Clinics | Madison | WI |
| UPMC - Shadyside Hospital | Pittsburgh | PA |